Dr. Modest Discusses the German AIO KRK0110 Study in CRC
Dominik P. Modest, MD, University of Munich, discusses the German AIO KRK0110 study in metastatic colorectal cancer (CRC).
AIO KRK0110 is a randomized phase III study of fluoropyrimide plus bevacizumab (Avastin) versus fluoropyrimide plus irinotecan and bevacizumab as first-line therapy for metastatic CRC.
This sequence study aims to answer the question of de-escalation in this patient population.